Skip to main content

Janux Therapeutics, Inc. (JANX)

Sector
Healthcare
Industry
Biotechnology
Last price
$10.92
As of

Kresmion compiles this page from JANX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Janux Therapeutics, Inc. (JANX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.

As of . Source: SEC EDGAR filings for JANX. Method and limitations.

COMPANY DOSSIER

See the full JANX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for JANX on one page. Preview it with sample data, then open it live with a free account.

Preview the JANX dossier

Active events for JANX

FREE, NO ACCOUNT

Every event on JANX, as it fires

You are seeing 5 of 17 events recorded on JANX since 2026-06-02.

The five above landed across 3 days. The other 12 were recorded on 4 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, JANX

More data on JANX

JANX against its peers

JANX's operating margin of -1576.7% ranks in the 21st percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricJANXPeer medianPercentilen
Revenue FY10.0M USD85.2M USD2111
Operating margin-1576.7%-98.2%2111
Net margin-1136.3%-101.1%2111
Return on equity-11.9%-50.5%8820
1 year-62.1%4.7%720

Peers (21): SGMT, AURA, SLDB, XOMA.D, PRME, LXRX, ORIC, NVCT, ACHV, ARDX, GLUE, DBVT, ANNX, IRWD, AVBP, FDMT, OLMA, SNDX, KURA, IMMX, RIGL. Left out: OBX (no annual filing), ATTO (no annual filing), APMD (no annual filing), LTGO (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (JANX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in JANX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on JANX in the last 180 days.

Upstream: SEC EDGAR filings for JANX

Kresmion, "Janux Therapeutics, Inc. (JANX) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/JANX. Upstream data: SEC EDGAR filings for JANX.

Link to this data (HTML):

<a href="https://kresmion.com/research/JANX">Janux Therapeutics, Inc. (JANX) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow JANX on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to JANX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the JANX dossier
Share

The JANX intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.